WO2019059550A3 - COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS - Google Patents

COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS Download PDF

Info

Publication number
WO2019059550A3
WO2019059550A3 PCT/KR2018/009976 KR2018009976W WO2019059550A3 WO 2019059550 A3 WO2019059550 A3 WO 2019059550A3 KR 2018009976 W KR2018009976 W KR 2018009976W WO 2019059550 A3 WO2019059550 A3 WO 2019059550A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucan
supplement
preventing
composition
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/009976
Other languages
English (en)
Korean (ko)
Other versions
WO2019059550A2 (fr
Inventor
이종대
류제필
최승인
김제경
장용만
김민지
박은지
양철수
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUEGEN BIOTECH CO Ltd
Original Assignee
GUEGEN BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180101389A external-priority patent/KR102133218B1/ko
Application filed by GUEGEN BIOTECH CO Ltd filed Critical GUEGEN BIOTECH CO Ltd
Priority to JP2020515700A priority Critical patent/JP2020533394A/ja
Priority to CN201880060863.4A priority patent/CN111107844A/zh
Priority to US16/609,734 priority patent/US20200206291A1/en
Publication of WO2019059550A2 publication Critical patent/WO2019059550A2/fr
Publication of WO2019059550A3 publication Critical patent/WO2019059550A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou traiter l'obésité, cette composition contenant un complément destiné à réduire la masse adipeuse et du β-glucane pour principes actifs.
PCT/KR2018/009976 2017-09-19 2018-08-29 COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS Ceased WO2019059550A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020515700A JP2020533394A (ja) 2017-09-19 2018-08-29 体脂肪減少補助剤およびベータグルカンを有効成分とする肥満の予防または治療用組成物
CN201880060863.4A CN111107844A (zh) 2017-09-19 2018-08-29 包含体脂减少助剂及β-葡聚糖作为有效成分的肥胖预防或治疗用组合物
US16/609,734 US20200206291A1 (en) 2017-09-19 2018-08-29 Composition for preventing or treating obesity, comprising supplement for reducing body fat and b-glucan as active ingredients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170120338 2017-09-19
KR10-2017-0120338 2017-09-19
KR1020180101389A KR102133218B1 (ko) 2017-09-19 2018-08-28 체지방 감소 보조제 및 베타글루칸을 유효성분으로 하는 비만 예방 또는 치료용 조성물
KR10-2018-0101389 2018-08-28

Publications (2)

Publication Number Publication Date
WO2019059550A2 WO2019059550A2 (fr) 2019-03-28
WO2019059550A3 true WO2019059550A3 (fr) 2019-05-09

Family

ID=65809689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009976 Ceased WO2019059550A2 (fr) 2017-09-19 2018-08-29 COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS

Country Status (1)

Country Link
WO (1) WO2019059550A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
KR20080064703A (ko) * 2007-01-04 2008-07-09 주식회사 글루칸 β-글루칸 및 길경 추출물을 유효성분으로 포함하는 항비만조성물
KR20100046348A (ko) * 2008-10-27 2010-05-07 (주)큐젠바이오텍 면역 증진 및 다이어트 효과를 갖는 천연 바이오폴리머의 다이어트 식품으로써의 용도
KR20110027717A (ko) * 2008-05-29 2011-03-16 메-에크 아에스 1,3／1,6 베타 글루칸을 포함하는 체중 감량용 조성물
KR20140073631A (ko) * 2012-11-30 2014-06-17 (주)아모레퍼시픽 잎새버섯 자실체 추출물을 포함하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
KR20080064703A (ko) * 2007-01-04 2008-07-09 주식회사 글루칸 β-글루칸 및 길경 추출물을 유효성분으로 포함하는 항비만조성물
KR20110027717A (ko) * 2008-05-29 2011-03-16 메-에크 아에스 1,3／1,6 베타 글루칸을 포함하는 체중 감량용 조성물
KR20100046348A (ko) * 2008-10-27 2010-05-07 (주)큐젠바이오텍 면역 증진 및 다이어트 효과를 갖는 천연 바이오폴리머의 다이어트 식품으로써의 용도
KR20140073631A (ko) * 2012-11-30 2014-06-17 (주)아모레퍼시픽 잎새버섯 자실체 추출물을 포함하는 조성물

Also Published As

Publication number Publication date
WO2019059550A2 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
PH12019502279A1 (en) Cleaning compositions and uses thereof
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
CA2906880C (fr) Aliment enrichi pour poisson
EP4378535A3 (fr) Formulations antibiotiques pour la douleur lombaire
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
WO2019111115A3 (fr) Oligosaccharides du lait humain pour le traitement de la migraine
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
PH12021550122A1 (en) Solubilized apyrases, methods and use
EP4616848A3 (fr) Formulations de linézolide
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
CA3011003A1 (fr) Fantomes bacteriens pour le traitement du cancer
WO2019059722A3 (fr) Composition pour le traitement de la cellulite, et micro-aiguille comprenant celle-ci
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2019059549A3 (fr) COMPOSITION POUR LE SOULAGEMENT DE LA GUEULE DE BOIS OU COMPOSITION POUR LA PRÉVENTION, LE SOULAGEMENT OU LE TRAITEMENT DE LA MALADIE HÉPATIQUE ALCOOLIQUE, COMPRENANT DU β-GLUCANE EN TANT QUE PRINCIPE ACTIF
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.
WO2019059550A3 (fr) COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS
WO2016135456A3 (fr) Aortopathie
CA3041260C (fr) Composition renfermant de l'allulose servant a promouvoir l'excretion des lipides vegetaux du corps
PH12018502568A1 (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
EP3723766A4 (fr) Composition et procédé de traitement, d'atténuation ou de prévention de crampes musculaires, contenant de l'alfoscérate de choline en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18858053

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020515700

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18858053

Country of ref document: EP

Kind code of ref document: A2